Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study
AI Summary
Biogen's new Alzheimer's drug aimed at targeting tau showed mixed outcomes during its mid-stage trials. The results could influence future treatment options and market strategies.